Immune checkpoint antibodies used in hematologic malignancies
| Ipilimumab | Nivolumab | Pembrolizumab | Pidilizumab | Atezolizumab | |
|---|---|---|---|---|---|
| Target | CTLA4 | PD1 | PD1 | PD1 | PD-L1 |
| Class | Humanized IgG1 | Human IgG4 | Humanized IgG4 | Humanized IgG1 | Humanized IgG1 |
| FDA approved indication | Unresectable or metastatic melanoma or in the adjuvant setting | Unresectable or metastatic melanoma; metastatic NSCLC; advanced renal cell carcinoma | Unresectable or metastatic melanoma; metastatic NSCLC | None at this time. Promising data in DLBCL and FL | None at this time. Ongoing trial in MM |
| Pharmaceutical | Bristol-Myers Squibb | Bristol-Myers Squibb | Merck | Cure Tech/Medivation | Genentech/Roche |
DLBCL, diffuse B cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma; NSCLC, non-small cell lung cancer.